find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
351
Clinical Trials
Breast Cancer Clinical Trials
Phase III
Enrolling
nct/study# NCT06435429 / JZP598-303
A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to previous trastuzumab deruxtecan treatment EmpowHER-303
Learn More
Breast Cancer Clinical Trials
N/A
Enrolling
nct/study# NCT06401421 / EXACTDNA-003
Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease (NSABP B-64)
Learn More
Breast Cancer Clinical Trials
Phase III
Enrolling
nct/study# NCT06876714 / A012303
ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade
Learn More
Breast Cancer Clinical Trials
Phase III
Enrolling
nct/study# NCT06671912 / A012301
LOTAM: A RANDOMIZED, PHASE III CLINICAL TRIAL OF LOW-DOSE TAMOXIFEN FOR SELECTED PATIENTS WITH MOLECULAR LOW-RISK EARLY-STAGE BREAST CANCER
Learn More
Breast Cancer Clinical Trials
Unspecified
Enrolling
nct/study# NCT05812807 / A012103
OPTIMICE-PCR: DE-ESCALATION OF THERAPY IN EARLY-STAGE TNBC PATIENTS WHO ACHIEVE PCR AFTER NEOADJUVANT CHEMOTHERAPY WITH CHECKPOINT INHIBITOR THERAPY
Learn More
Breast Cancer Clinical Trials
Phase III
Enrolling
nct/study# NCT05894239 / WO44263
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination with Phesgo Versus Placebo in Combination with Phesgo as Maintenance Therapy After First Line Induction Therapy in Participants with PIK3CA Mutated HER2 Positive Locally Advanced or Metastatic Breast Cancer
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.